Phaseline

Targets › ITGA

ITGA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2028.

Open in Phaseline: the race on ITGA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TwoStep TherapeuticsTS-104
Peptide-drug conjugate (PDC) delivering monomethyl auristatin E (MMAE) via integrin-target
ITGA, ITGBPhase 1NSCLC (Non-small Cell Lung Cancer)Aug 2028

Conditions

NSCLC (Non-small Cell Lung Cancer) (1)

Modalities

small molecule (1)

Companies

TwoStep Therapeutics (1)

Related targets

ITGB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.